Mark Humayun named inaugural director of the USC Eye Institute

November 14, 2013

FOR IMMEDIATE RELEASE
Wednesday, Nov. 13, 2013

Contact: Leslie Ridgeway at (323) 442-2823 or lridgewa@usc.edu

LOS ANGELES —Mark Humayun, M.D., Ph.D., internationally known for his work on the Argus II artificial retina implant intended to restore sight to the blind, has been named the inaugural director of the University of Southern California (USC) Eye Institute and interim chair of the USC Department of Ophthalmology.

In his new role, Humayun takes the reins of a local and national leader in eye care services, providing advanced surgical techniques and comprehensive care for patients. Humayun will also continue to lead and guide cutting edge transformative research.

“The USC Eye Institute and the USC Department of Ophthalmology together offer a top-ranked clinical practice and world-class research with the potential to cure prevalent and challenging diseases of the eye,” said Humayun. “The groundbreaking work at the USC Eye Institute will lead to transformative new solutions for preserving and restoring sight and the USC Department of Ophthalmology will be the conduit that provides these treatments safely and effectively to patients with vision problems.”

Humayun is professor of ophthalmology, biomedical engineering and cell and neurobiology at the Keck School of Medicine of USC and the USC Viterbi School of Engineering. He is a University Professor (the highest recognition for a professor at USC) and also is the inaugural Cornelius J. Pings Chair in Biomedical Sciences. He is a member of both the USA National Academies Institute of Medicine and the National Academy of Engineering.

In a joint statement, Elizabeth Garrett, USC provost and senior vice president for academic affairs, Carmen Puliafito, M.D., M.B.A, dean of the Keck School of Medicine of USC, and Tom Jackiewicz, senior vice president and CEO for USC Health, expressed their support for Humayun.

“We look forward to his continued commitment to the highest levels of basic and translational research through his leadership of the USC Eye Institute,” the statement said, adding that they “are confident that USC’s tradition of strong leadership will be maintained.”

Working closely with physicians and researchers to enable them to do their best in clinical practice as well as translational and basic vision research is a priority for Humayun.

“We plan to achieve our new goals through continued emphasis on clinical, research and educational missions,” he said.

Over the past decade, USC’s ophthalmology services have consistently ranked in the top 10 in U.S. News & World Report “Best Hospitals” rankings.

Humayun is internationally recognized for his work on the treatment of the most debilitating and challenging eye diseases through advanced engineering. This includes the development of therapies for retinal degenerations such as retinitis pigmentosa; macular degenerations such as age-related macular degeneration; retinovascular diseases such as vein occlusions; diabetic retinopathy and retinal detachments. Humayun was the principal member of a team that developed the Argus II implant, which has been shown to restore sight to some people blinded by retinitis pigmentosa (RP). The Argus II (manufactured and sold by Second Sight Medical Products) was approved for use in the United States by the US Food and Drug Administration in February 2013.

Photo: Mark Humayun with the Argus II artificial retina implant. Photo by Jon Nalick.

###

ABOUT KECK MEDICINE OF USC
Keck Medicine of USC is the University of Southern California’s medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area. Encompassing academic, research and clinical entities, it consists of the Keck School of Medicine of USC, one of the top medical schools in Southern California; the renowned USC Norris Comprehensive Cancer Center, one of the first comprehensive cancer centers established in the United States; the USC Care faculty practice; the Keck Medical Center of USC, which includes two acute care hospitals: 411-bed Keck Hospital of USC and 60-bed USC Norris Cancer Hospital; and USC Verdugo Hills Hospital, a 158-bed community hospital. It also includes outpatient facilities in Beverly Hills, downtown Los Angeles, La Cañada Flintridge, Pasadena, and the USC University Park Campus. USC faculty physicians and Keck School of Medicine departments also have practices throughout Los Angeles, Orange and Riverside counties.